April 18th 2024
Researchers were unable to find a significant benefit for patients for the majority of cancer medications given accelerated FDA approval.
CMS Releases Revised Guidance for Medicare Price Negotiation
June 30th 2023In the revised guidance, CMS clarified aspects of the negotiation process and outlined additional opportunities for engagement during the process. CMS will publish by Sept. 1, 2023, the list of the first 10 drugs for price negotiation.
Read More
Alex Jung: It’s time to Think Differently about Specialty Drugs
June 21st 2023Employers and plans need to prioritize clinical efficacy over drug price, look for price reductions — and not rebates — on biosimilars, and advocate for a public option to cover gene therapies. These are just a few of ideas that consultant Alex Jung put forward at a meeting of the Midwest Business Group on Health.
Read More
Coherus Announces Lowest Price for Humira Biosimilar, Partners with Mark Cuban Cost Plus
June 2nd 2023Coherus will launch Yusimry in July with a list price of $995 per carton (2 x 40 mg/0.8 mL autoinjectors); “the lowest price announced to date of any adalimumab offering in the United States,” the company said.
Read More